<DOC>
	<DOCNO>NCT01933672</DOCNO>
	<brief_summary>Study B1621019 ass efficacy safety two different dose regimen investigational agent ( PF-04937319 ) compare approve drug ( sitagliptin ) patient type 2 diabetes</brief_summary>
	<brief_title>Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent ( Sitagliptin ) In Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients type 2 diabetes , background metformin therapy either alone 1 oral antidiabetic agent ( exclude Actos ) Patients cardiovascular event within 6months screen Patients diabetic complication Female subject pregnant plan become pregnant Subjects unstable medical condition ( eg , hypertension )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1b</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>metformin background</keyword>
	<keyword>PF-04937319</keyword>
</DOC>